Key result
Treatment-induced change in pulmonary vascular resistance after 4 months better explained changes in ESC/ERS risk classification than baseline or 4-month absolute values.
Why the study?
In pulmonary arterial hypertension, it remains unclear whether absolute haemodynamic values or treatment-induced changes are more relevant to subsequent changes in clinical status.
Does treatment-induced change in PVR better explain risk change in PAH compared to absolute PVR values?
Cohort (n=69)
Does treatment-induced change in PVR better explain risk change in PAH compared to absolute PVR values?
Treatment-induced change in PVR after 4 months outperforms absolute baseline or 4-month PVR in explaining changes in ESC/ERS 4-strata risk classification in PAH.
Answers are grounded in this paper and cite their sources.
May inform serial PVR monitoring for risk shifts in PAH; hypothesis-generating and should not yet change practice.
INTRODUCTION In pulmonary arterial hypertension (PAH), it remains unclear whether absolute haemodynamic values or treatment-induced changes are more relevant to subsequent changes in clinical status.As risk classifications are increasingly used to guide clinical management, we evaluated whether pulmonary vascular resistance (PVR) at baseline, after 4 months of therapy, or treatment-induced change better explains risk change.METHODS Among 104 screened PAH patients, 69 were included retrospectively.The primary outcome was change in clinical status, defined as a shift in ESC/ERS 4-strata risk classification from baseline to 15 months.Haemodynamics were evaluated via right heart catheterization before and after 4 months of pharmacotherapy.Linear regression examined associations of baseline PVR, 4-month PVR, and PVR with risk change.ROC analyses explored the ability of PVR (baseline, 4-month, and ), RVEDP, and CI to discriminate between risk stabilisation and worsening.RESULTS Risk classification and PVR decreased significantly following treatment (p<0.001).PVR had the highest partial explained variance for risk change (R 2 =0.118, p=0.003), followed by baseline PVR (R 2 =0.098, p=0.013).4-Month PVR did not significantly predict risk classification change.In ROC analyses, only PVR significantly discriminated risk stabilisation (AUC=0.75,p<0.001).Bootstrapping and permutation confirmed the robustness of these findings.CONCLUSIONS The change in PVR after 4 months of treatment outperformed baseline and 4-month PVR, but also other dynamic measures (RVEDP and CI), in explaining changes in 4-strata risk classification and identifying risk stabilisation.These findings suggest that PVR provides complementary insight when interpreting serial haemodynamic evaluations in the context of early treatment response in PAH.
No takes yet. Share an insight, caveat, or question.
Donker et al. (2026) conducted a cohort in Pulmonary arterial hypertension (n=69). Change in pulmonary vascular resistance (PVR) vs. Baseline PVR and 4-month PVR was evaluated on Change in clinical status, defined as a shift in ESC/ERS 4-strata risk classification from baseline to 15 months (R2 0.118, p=0.003). Treatment-induced change in pulmonary vascular resistance after 4 months better explained changes in ESC/ERS risk classification than baseline or 4-month absolute values.
Synapse has enriched 10 related papers. Consider them for comparative context: